News

Dupixent, a Sanofi and Regeneron Pharmaceuticals drug, is now approved for chronic obstructive pulmonary disease (COPD), a progressive lung disease prevalent in smokers. It’s the sixth FDA ...
Sanofi’s prescription drug Dupixent confirmed its promise in helping patients with a chronic lung disorder, potentially speeding the process for the blockbuster medicine to gain another avenue ...
But Sanofi isn’t only counting on Dupixent for growth. Vaccines are another key piece of the company’s strategy, and those products pulled in €1 billion for the quarter, a 16% increase.
Sanofi and Regeneron, which co-sell the drug, spent a massive $287.6 million on Dupixent ads last year, making them the highest of all pharma drug spenders in 2021.
Sanofi expects Dupixent to achieve more than €13 billion in peak sales. Dupixent now is approved in the United States and the EU for three type II inflammatory diseases, ...
Investors will focus on profits from asthma drug Dupixent and sales of Eylea HD when biotech giant Regeneron Pharmaceuticals, ...
FDA approves asthma indication for Dupixent® (dupilumab) Only biologic approved for both moderate and severe asthma patients with eosinophilic phe ...
If approved, Dupixent would gain access to an addressable market of at least 75,000 patients. This indication could generate $1.4 billion in annual revenue for Sanofi and Regeneron to split. The ...
Sanofi plans to seek U.S. approval for its best-selling anti-inflammatory drug Dupixent to be used in the treatment of "smoker's lung", also known as COPD, after a second large trial showed ...
Sanofi SNY and partner Regeneron REGN announced positive top-line data from the second pivotal phase III study on their blockbuster medicine Dupixent (dupilumab) for treating adult patients with ...
Dupixent's fourth-quarter sales surged 135%, annual sales soared 152% to $2.3 billion, and according to Sanofi, the drug is on its way to the goal of generating peak sales of $11 billion.
Dupixent ® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis Only biologic approved in the European Union for patients aged 12 and above with ...